PMI’s FDA-approved SynCardia STAH is promising, but adoption and revenues lag; cash burn and dilution weigh. Read the full ...
A single overlooked ratio is flashing a rare historical signal. Years of underperformance may have created a powerful setup.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback